Pharmaceutical

Iruplinalkib by Qilu Pharmaceutical for Solid Tumor: Likelihood of Approval

Iruplinalkib is under clinical development by Qilu Pharmaceutical and currently in Phase II for Solid Tumor.

Dec 22, 2023 - 18:00
Iruplinalkib is under clinical development by Qilu Pharmaceutical and currently in Phase II for Solid Tumor.
Read the original article

Tags:

Previous Article

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval

Next Article

XB-002 by Exelixis for Breast Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Appeals court upholds limits to abortion pill

Appeals court upholds limits to abortion pill

Aug 17, 2023

STAT+: Pear Therapeutics sold for parts at $6 million auction

STAT+: Pear Therapeutics sold for parts at $6 million a...

May 19, 2023

Lantidra wins FDA approval as first-ever type 1 diabetes cell therapy

Lantidra wins FDA approval as first-ever type 1 diabete...

Jun 29, 2023